Furthermore, anemia and elevated levels of serum CEA, CA19–9 were frequently detected among 80% (28/35), 60% (21/35), 42.9% (15/35) of AFP-producing GC patients, particularly for those with serosal involvement, lymphatic and venous invasion, and lymph node metastasis. This evidence concerns the gene AFP and gastric cancer.